BioPharma Intelligence Hub

FDA catalyst tracker, drug pipeline monitor & clinical trial data for 954 biotech companies. Free data from FDA, SEC EDGAR & ClinicalTrials.gov.

Upcoming Catalysts

No upcoming catalysts in the next 14 days. Data is being populated.

BioPharma Companies

Ticker Company Sector Grade
FDMT 4D Molecular Therapeutics, Inc. Biotechnology D
SXTP 60 DEGREES PHARMACEUTICALS, INC. Pharmaceutical D
SXTPW 60 DEGREES PHARMACEUTICALS, INC. Pharmaceutical
AARD Aardvark Therapeutics, Inc. Pharmaceutical D
ABT ABBOTT LABORATORIES Pharmaceutical A+
ABBV AbbVie Inc. Pharmaceutical A+
ABCL AbCellera Biologics Inc. Pharmaceutical D
ABEO ABEONA THERAPEUTICS INC. Pharmaceutical D
AAVXF Abivax S.A. Pharmaceutical
ABVX Abivax S.A. Pharmaceutical D
View All Companies →

What is the BioPharma Intelligence Hub?

A free, data-driven platform that aggregates information from official US government sources to help you track pharmaceutical and biotechnology company developments. All data comes from public domain sources: the U.S. Food & Drug Administration (FDA), the Securities and Exchange Commission (SEC EDGAR), and the National Library of Medicine (ClinicalTrials.gov).

Catalyst Calendar

Track upcoming PDUFA dates, AdCom meetings, Phase 3 readouts, and other FDA regulatory events.

View Calendar →

Company Pipelines

Explore drug pipelines for 800+ biotech and pharma companies with trial status and regulatory timelines.

Browse Companies →

Clinical Trials

Monitor active clinical trials from ClinicalTrials.gov, organized by company, phase, and indication.

SEC Filings

FDA-related 8-K filings parsed and organized by company. Direct links to SEC EDGAR source documents.

Pipeline Development Grades

Companies are assessed using a transparent, published methodology based on objective data points. Grades reflect pipeline development progress, not investment merit.

A+ Strong pipeline: 18+ months cash runway, Phase 3+ programs, upcoming catalysts
A Above average: Adequate cash, advancing pipeline, identifiable catalysts
B Standard profile: Mixed signals, adequate cash but limited near-term catalysts
C Elevated risk factors: Limited cash runway, early-stage only, trial setbacks
D Significant concerns: Cash constraints, multiple trial failures, regulatory warnings

Read the full methodology →